Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)
CNY 5.15
(0.0%)
CNY 5.15
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -708.27 Million CNY | 19.99% |
| 2022 | -885.28 Million CNY | -162.84% |
| 2021 | -336.81 Million CNY | -6.69% |
| 2020 | -315.68 Million CNY | -22.79% |
| 2019 | -257.1 Million CNY | -310.33% |
| 2018 | -62.65 Million CNY | 61.4% |
| 2017 | -162.3 Million CNY | -291.93% |
| 2016 | -41.41 Million CNY | 11.69% |
| 2015 | -46.89 Million CNY | 56.24% |
| 2014 | -107.16 Million CNY | -71.61% |
| 2013 | -62.44 Million CNY | -168.18% |
| 2012 | -23.28 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -631.94 Million CNY | -7.71% |
| 2024 Q3 | -824.84 Million CNY | -29.55% |
| 2024 Q1 | -586.7 Million CNY | 17.16% |
| 2023 Q3 | -670.16 Million CNY | -6.17% |
| 2023 Q4 | -708.27 Million CNY | -5.69% |
| 2023 FY | -708.27 Million CNY | 19.99% |
| 2023 Q1 | -794.62 Million CNY | 10.24% |
| 2023 Q2 | -631.2 Million CNY | 20.57% |
| 2022 Q4 | -885.28 Million CNY | -54.9% |
| 2022 FY | -885.28 Million CNY | -162.84% |
| 2022 Q1 | -398.28 Million CNY | -18.25% |
| 2022 Q2 | -376.3 Million CNY | 5.52% |
| 2022 Q3 | -571.5 Million CNY | -51.87% |
| 2021 Q3 | -300.04 Million CNY | -201.7% |
| 2021 Q2 | -99.45 Million CNY | 67.57% |
| 2021 Q4 | -336.81 Million CNY | -12.26% |
| 2021 FY | -336.81 Million CNY | -6.69% |
| 2021 Q1 | -306.69 Million CNY | 2.85% |
| 2020 Q1 | -219.79 Million CNY | 14.51% |
| 2020 Q4 | -315.68 Million CNY | 71.17% |
| 2020 FY | -315.68 Million CNY | -22.79% |
| 2020 Q2 | -20.85 Million CNY | 90.51% |
| 2020 Q3 | -1.09 Billion CNY | -5150.38% |
| 2019 Q1 | -67.26 Million CNY | -7.35% |
| 2019 FY | -257.1 Million CNY | -310.33% |
| 2019 Q3 | -48.91 Million CNY | 19.41% |
| 2019 Q4 | -257.1 Million CNY | -425.59% |
| 2019 Q2 | -60.7 Million CNY | 9.75% |
| 2018 FY | -62.65 Million CNY | 61.4% |
| 2018 Q4 | -62.65 Million CNY | 20.94% |
| 2018 Q3 | -79.25 Million CNY | 55.13% |
| 2018 Q2 | -176.62 Million CNY | 6.86% |
| 2018 Q1 | -189.63 Million CNY | -2.08% |
| 2017 Q3 | -191.48 Million CNY | -72.16% |
| 2017 Q4 | -185.75 Million CNY | 2.99% |
| 2017 FY | -162.3 Million CNY | -291.93% |
| 2017 Q1 | -29.53 Million CNY | 28.67% |
| 2017 Q2 | -111.22 Million CNY | -276.55% |
| 2016 Q1 | 47.25 Million CNY | 0.0% |
| 2016 Q2 | -39.31 Million CNY | -183.21% |
| 2016 Q4 | -41.41 Million CNY | 0.0% |
| 2016 FY | -41.41 Million CNY | 11.69% |
| 2015 FY | -46.89 Million CNY | 56.24% |
| 2014 FY | -107.16 Million CNY | -71.61% |
| 2013 FY | -62.44 Million CNY | -168.18% |
| 2012 FY | -23.28 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.31 Billion CNY | 153.725% |
| Hangzhou Tigermed Consulting Co., Ltd. | -4.06 Billion CNY | 82.565% |
| Dirui Industrial Co.,Ltd. | -131.62 Million CNY | -438.119% |
| Beijing Strong Biotechnologies, Inc. | 411.59 Million CNY | 272.083% |
| Medicalsystem Biotechnology Co., Ltd. | -850.71 Million CNY | 16.743% |
| Maccura Biotechnology Co.Ltd | -170.79 Million CNY | -314.702% |
| Guangzhou Wondfo Biotech Co.,Ltd | -240.75 Million CNY | -194.188% |
| BGI Genomics Co., Ltd. | -3.63 Billion CNY | 80.52% |
| Amoy Diagnostics Co., Ltd. | -92.73 Million CNY | -663.797% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -486.57 Million CNY | -45.564% |